Skip to main content
OpenTrials
Completed

NCT Number: NCT00111891

An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)

This is a 3-week trial in normal healthy or lipid clinic patients studying a novel approach to treating dyslipidemia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Dyslipidemia Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

25 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

About this study

The duration of treatment is 7 days.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females (ages 25-75)

Exclusion criteria

  • A condition which, in the opinion of the investigator, might pose a risk to the patient or interfere with participating in the study

Treatment and study plan

niacin (+) laropiprant

Drug

Other names: MK0524A

Comparator: Placebo (Unspecified)

Drug

Primary outcomes

  1. Acute cutaneous symptoms induced by niacin for 7 days.

    Time frame: 7 days

Secondary outcomes

  1. Tolerability

    Time frame: 7 days

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

A Dose Ranging Study to Evaluate the Tolerability of MK0524 (Niacin (+) Laropiprant) and Its Effects on Niacin-Induced Acute Flushing in Lipid Clinic Patients and/or Normal Healthy Subjects

Important dates

Study start
2005
Primary completion
2005
Study completion
2005
First posted
May 27, 2005
Registry last updated
Feb 17, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.